# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and lowers the ...
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate o...
B. Riley Securities analyst Mayank Mamtani downgrades Cognition Therapeutics (NASDAQ:CGTX) from Buy to Neutral and lowers th...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and lowers the ...
Cantor Fitzgerald analyst Charles Duncan downgrades Cognition Therapeutics (NASDAQ:CGTX) from Overweight to Neutral.
Cognition Therapeutics' Phase 2 'SHINE' study shows CT1812 leads to cognitive improvement in Alzheimer's patien...